Samuel Waksal, the ex-ImClone Systems CEO who served 5 years in prison for securities fraud, has made a comeback in the biotech arena with his new company, Kadmon Pharmaceuticals. Kadmon has acquired privately held Three Rivers Pharmaceuticals for more than U$100 M and has signed two hepatitis C deals with Valeant Pharmaceuticals.